164 results
8-K
EX-99.1
52sa8s79yuyip
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
8-K
EX-10.1
fg3se8 ol3di
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
lau69j7epw2 kz115l7n
14 Feb 24
Other Events
4:11pm